India reports 91,702 #Covid-19 cases, 1,34,580 discharges & 3,403 deaths in last 24 hrs, as per Health Ministry.
Total cases: 2,92,74,823
Total discharges: 2,77,90,073
Death toll: 3,63,079
Active cases: 11,21,671
Total vaccination: 24,60,85,649
India reports 94,052 Covid cases in 24 hours with 1,51,367 discharges. 6148 deaths were reported in 24 hours, the highest number of single day deaths, as per a report by Health Ministry.
Total cases: 2,91,83,121
Total discharges: 2,76,55,493
Death toll: 3,59,676
Active cases: 11,67,952
The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Express of Interest (EOI) to transfer the technology to Indian pharmaceutical industries for production.
The 2-DG is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’ Laboratories.
The third phase trials of 2-DG began in January, while the phase trials were conducted over three month period between June and September last year and involved 110 patients.
The DCGI had granted permission in May last year to Dr Reddy’s Laboratories for conducting a clinical trial of 2 DG for “acute treatment of moderate to severe Covid-19 patients.”
The government has recently launched 2-DG as an anti -Covid-19 therapeutic application of the drug 2-Deoxy-D-glucose (2-DG).
Patients treated with 2-DG have shown negative RT-PCR in COVID-19 patients.
India has reported cases below 1 Lakh mark. 86,498 cases were reported in the last 24 hours. 1,82,282patients recovered during last 24 hours.
The country reported 2123 deaths in last 24 hours, the lowest in 47 days, according to a data by health ministry.
Total active cases: 1,308,806
Total recoveries: 2,73,41,462
Death Toll: 3,51,344
Total vaccines administered: 23,47,43,489
Delhi’s Lok Nayak Jai Prakash Narayan Hospital (LNJP) ahad begun Monoclonal Antibody Cocktail used to treat mild to moderate “high risk” patients who are Covid positive, free of cost.
“We have received a Monoclonal Antibody Cocktail– a combination of Casirivimab and Imdevimab. We have started using it in LNJP hospital. Now we will be able to provide the latest medicines for the Covid-19 patients. These are the monoclonal antibodies and they are very useful,” said Dr Suresh Kumar, Managing Director, LNJP hospital”We will have first-time experience of these drug cocktails or antibody cocktails.
Earlier patients were going to the private hospitals to get this treatment, but now the government has made a provision and we are giving it in LNJP. We are giving it free of cost.”Roche India and Cipla had announced the launch of the Antibody Cocktail in India last week.
Priced at ₹59,750 for a dose, the therapy has been earlier introduced in private hospitals Fortis Escorts, Moolchand, Apollo, Sir Gangaram, and Max Hospital.
Union Health Minister Harsh Vardhan on Monday said that seven states, including Delhi and Haryana, have less than 1,000 COVID-19 cases.The other states where COVID-19 cases are below 1,000 are Madhya Pradesh, Rajasthan, Gujarat, Uttarakhand and Jharkhand.
Addressing the meeting of the Group of Ministers on the COVID19 situation in the country, he said, “As of today, we have 14,01,609 active cases in the country.”He further said that the country’s recovery rate is continuously climbing up.
“Around 83 per cent of active cases are in 10 states and the remaining 17 per cent are in 26 states and UTs,” he said.He also said that five states, including Jammu and Kashmir, Punjab, Bihar Chhattisgarh, Uttar Pradesh have less than 2,000 coronavirus cases.
“In the most-affected states, Maharashtra, Kerala, Tamil Nadu, Karnataka, there is a decline in the number of cases and it is significant,” Vardhan added.
India reports 1.20 Lakh Daily New Cases in last 24 hours, lowest in 58 days.
India’s Active Caseload further decreases to 15,55,248.
1,97,894 patients have recovered during last 24 hours.
Total recoveries: 2,67,95,549
Total vaccination: 22,65,08,508
New Delhi: The only Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of Covid-19 has been given permission to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), according to sources.
“SEC gives a recommendation for the Phase I and II clinical trials of Zydus Cadila’s biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) that can emerge as one of the main treatments for mild Covid-19,” the sources said.
These antibodies are made by cloning unique white blood cells. Domestic pharmaceutical major Zydus Cadila sought the Drug Controller General of India (DCGI) permission recently to undertake clinical trials.
Hyderabad: A day after Virinchi Hospital’s permission to treat COVID-19 patients was revoked, the state government on Saturday also barred five more private hospitals from admitting COVID-19 patients based on complaints from the public. So far the Telangana State Public Health and Family Welfare department’s director has taken the same action against 10 health care centres in Hyderabad.
According to a statement from Dr. G. Srinivasa Rao, director, Public Health and Family Welfare department, the five hospitals whose permission was revoked on Saturday are: Image Hospital (Ameerpet), Ankura Hospita (LB Nagar), Sia Life Hospital (Kondapur), Panchavati Hospital (Bhoothpur, Mahbubnagar) and Sai Siddartha Hospita (Shapur Nagar, Sanga Reddy).
The action taken against these hospitals was primarily with regard to complaints of excess and irrelevant charges in addition to the prescribed norms, mismanagement and lack of proper attention with regard to treating COVID-19 patients. The department has so far received a total of 115 complaints at different dates from the public which has led to the state government also issuing show cause notices to 79 hospitals. Aside from that, a total of 10 hospitals so far have had their permissions to treat COVID-19 patients revoked.
The director also warned that any hospital found guilty of violating established protocols, norms, and guidelines will be subjected to suitable disciplinary action. In Hyderabad and Telangana, ever since the onset of the ongoing second wave of the COVID-19 virus, bed hospitals have been charging patients exorbitant amounts, ranging between Rs.40000 to as much as Rs.1 lakh per day for a bed (depending on requirement for oxygen and ventilators).
A day earlier on May 28, the state government Friday revoked the permission of Virinchi Hospital at Banjara Hills to treat COVID-19 patients, after a complaint was filed against it for medical negligence by its doctors and staff, and for violating treatment protocols. The complaint was lodged by relatives of a man named Vamsi Krishna, who died there while undergoing treatment two days ago, after which some of his relatives ransacked the healthcare centre.
The order revoking Virinchi Hospital’s permission to treat COVID-19 patient was signed by Telangana’s Publuch Health and Family Welfare department director, who issued a show cause notice to the hospital after the complaint was lodged. “But, the hospital parties failed to submit any explanation to the show cause notice issued by this office regarding medical negligence in treating theCOVID-19 patient,” said the director’s order, dated May 28.
At-home Covid-19 tests should be available in the market in the next three to four days, the Indian Council of Medical Research (ICMR) said on Thursday.
While speaking at a press briefing in Delhi, Dr Balram Bhargava, Director General of the ICMR informed that results for home COVID testing will be processed and delivered through a mobile application.
“Step 1 is that you buy the test kit form a chemist, Step 2 – download the mobile app. Step 3 – conduct the test at home. Step 4 – click a mobile image and upload. The test result will be given,” Bhargava explained.
He added, “This ensures patient confidentiality, data is stored in a secure server and it is linked with the ICMR database. This should be available in the market within three to four days. One company has approval for home testing kits, three more are in the pipeline.”
Earlier on Thursday, Pune’s Mylab Discovery Solutions launched India’s first-ever self-testing kit for Covid-19, which has received the approval of the Indian Council of Medical Research (ICMR).
The ICMR DG further said that over 20 lakh tests were conducted on May 18 and 10 across the country, the highest even figures. Despite this, the positivity rate has dropped to about 13 per cent.
“In the middle of February till early March, we were doing about 8 lakh tests per day and have increased that to 20 lakh. Yet our positivity percentage has fallen to 13 per cent from 28 per cent. We have to bring it down to 5 per cent,” he said.
He added that they aim to do 25 lakh tests per day by the end of this month and 45 lakh tests by the end of June.
“More Rapid Antigen Tests should be done because you can get results rapidly and then isolate the patient quickly,” he added.
Bhargava further said that the Defence Research and Development Organization’s 2-DG drug is not a new medicine and has been repurposed.
“The DRDO’s 2-DG drug is a repurposed medicine, not a new medicine. It was earlier used for cancer treatment. Its trial results have been given to DCGI,” he said.
Speaking about the state-wise statis of COVID in the country, Lav Agarwal, Joint Secretary of the Union Health Ministry informed that eight in the country have more than 1 lakh active cases, nine states have between 50,000-1 lakh active cases and 19 states have less than 50,000 active cases.